7/13/2020 7:09:20 AM
Axsome Completes Successful FDA Pre-NDA Meeting For AXS-05
6/26/2020 7:06:26 AM
Axsome Therapeutics: FDA Grants Breakthrough Therapy Designation For AXS-05 For Alzheimer’s Disease Agitation
4/27/2020 6:04:31 AM
Axsome Therapeutics Says ADVANCE-1 Pivotal Phase 2/3 Trial Meets Primary Endpoint
4/6/2020 6:05:51 AM
Axsome Therapeutics: AXS-07 Meets Co-Primary Endpoints And Prevents Migraine Pain Progression In INTERCEPT Phase 3 Trial
3/30/2020 6:11:45 AM
Axsome Therapeutics Says AXS-05 Met Key Secondary Endpoints In STRIDE-1 Trial
3/5/2020 7:09:50 AM
Axsome Therapeutics Promotes Mark Jacobson To COO
1/22/2020 7:22:12 AM
Axsome Completes Patient Randomization In STRIDE-1 Phase 3 Trial Of AXS-05
12/30/2019 6:16:08 AM
Axsome Therapeutics Announces AXS-07 Meets Co-Primary And Key Secondary Endpoints In MOMENTUM Phase 3 Migraine Trial
12/19/2019 7:13:39 AM
Axsome Therapeutics Prices Public Offering Of 2 Mln Shares At $87/Shr
12/17/2019 7:11:43 AM
Axsome Therapeutics Says Elected For Addition To NASDAQ Biotechnology Index